Corvus Pharmaceuticals Stock Forecast, Price & News

Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

Is Corvus Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corvus Pharmaceuticals stock.
View analyst ratings for Corvus Pharmaceuticals or view top-rated stocks.

How has Corvus Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRVS stock has decreased by 34.7% and is now trading at $1.77.
View which stocks have been most impacted by COVID-19.

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 223,500 shares, a drop of 31.2% from the December 15th total of 324,700 shares. Based on an average daily volume of 763,900 shares, the short-interest ratio is presently 0.3 days. Currently, 0.7% of the company's stock are short sold.
View Corvus Pharmaceuticals' Short Interest.

When is Corvus Pharmaceuticals' next earnings date?

Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Corvus Pharmaceuticals.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its quarterly earnings data on Sunday, October, 31st. The company reported ($0.24) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.24).
View Corvus Pharmaceuticals' earnings history.

What price target have analysts set for CRVS?

4 equities research analysts have issued 1-year price objectives for Corvus Pharmaceuticals' stock. Their forecasts range from $3.50 to $8.00. On average, they anticipate Corvus Pharmaceuticals' share price to reach $6.38 in the next twelve months. This suggests a possible upside of 260.2% from the stock's current price.
View analysts' price targets for Corvus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the following people:

• Richard A. Miller, Chairman, President & Chief Executive Officer
• Leiv Lea, Chief Financial Officer
• Suresh Mahabhashyam, Vice President-Clinical Development
• Joseph J. Buggy, Executive Vice President-Discovery Research
• William B. Jones, Senior Vice President-Pharmaceutical Development

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals CEO Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among Corvus Pharmaceuticals' employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Corvus Pharmaceuticals' key competitors?

Some companies that are related to Corvus Pharmaceuticals include Avadel Pharmaceuticals (AVDL), Adagene (ADAG), Vaccitech (VACC), AC Immune (ACIU), Immuneering (IMRX), Nanobiotix (NBTX), Pyxis Oncology (PYXS), XBiotech (XBIT), Radius Health (RDUS), Cogent Biosciences (COGT), Sernova (SEOVF), VistaGen Therapeutics (VTGN), Viking Therapeutics (VKTX), Evolus (EOLS) and Rallybio (RLYB).
View all of CRVS's competitors.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cutler Group LP (0.00%). Company insiders that own Corvus Pharmaceuticals stock include Ecor1 Capital, Llc, Holdings A/S Novo, Orbimed Advisors Llc and Richard A Md Miller.
View institutional ownership trends for Corvus Pharmaceuticals.

Which institutional investors are selling Corvus Pharmaceuticals stock?

CRVS stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold Corvus Pharmaceuticals company stock in the last year include Ecor1 Capital, Llc, and Orbimed Advisors Llc.
View insider buying and selling activity for Corvus Pharmaceuticals or view top insider-selling stocks.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $1.77.

How much money does Corvus Pharmaceuticals make?

Corvus Pharmaceuticals has a market capitalization of $82.39 million. The company earns $-5.99 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals employs 42 workers across the globe.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

Where are Corvus Pharmaceuticals' headquarters?

Corvus Pharmaceuticals is headquartered at 863 Mitten Road Suite102, BURLINGAME CA, 94010.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at (650) 900-4520 or via email at [email protected].